| アブストラクト | Background: Eosinophilic esophagitis (EoE) is a rare, chronic immune-mediated disorder with limited treatment options. Despite the U.S. Food and Drug Administration (FDA) approval of dupilumab for EoE, other monoclonal antibodies remain unapproved and are used off-label with limited evidence on their efficacy and safety. This systematic review rigorously and comprehensively evaluates the evidence for monoclonal antibody therapies used off-label to treat EoE. Methods: We conducted a systematic review across PubMed, EMBASE, Cochrane Central, and ClinicalTrials.gov, assessing the efficacy and safety of off-label monoclonal antibodies in EoE through clinical outcomes and the FDA Adverse Event Reporting System (FAERS) data. Results: Among ten monoclonal antibodies reviewed, mepolizumab that targets IL-5 showed the most promise with a moderate recommendation based on Level 2 evidence. Others like omalizumab (anti-IgE), dectrekumab (anti-IL-13), and reslizumab (anti-IL-5) showed limited utility. Safety evaluations via the FAERS database revealed significant adverse drug reactions, including serious events like asthmatic crises, pneumonia, and adrenal insufficiency for mepolizumab and reslizumab, as well as chronic obstructive pulmonary disease and gastroenteritis for omalizumab. Dectrekumab's safety profile remains unclear due to a lack of data. Conclusions: While mepolizumab demonstrates potential as an off-label treatment, none of the antibodies reviewed have FDA approval for EoE. Clinicians should consider the balance between local and systemic effects and exercise caution, closely monitoring for adverse effects, particularly in patients with respiratory comorbidities. Continued research is crucial to establish a more robust evidence base for these therapies. |
|---|
| ジャーナル名 | Biomedicines |
|---|
| Pubmed追加日 | 2024/11/27 |
|---|
| 投稿者 | Yang, Benyu; Li, Wenhan; Gao, Yiqiang; Zhang, Bo; Zuo, Wei |
|---|
| 組織名 | Department of Pharmacy, Peking Union Medical College Hospital, 1 Shuaifuyuan;Wangfujing, Beijing 100730, China.;College of Pharmacy, University of Michigan-Ann Arbor, 428 Church St., Ann Arbor,;MI 48109, USA.;State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical;College Hospital, Chinese Academe of Medical Science, Beijing 100730, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39595142/ |
|---|
